A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
Completed · Phase 1 · NCT02942290
Conditions: Myelodysplastic Syndromes (MDS)
At a glance
- Research payments reported, 2025
- $27,079
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 134
About the trial
- Sponsor
- AbbVie (with Genentech, Inc.)
- Tested
- Azacitidine (drug), Venetoclax (drug)
- Dates
- Started 2017-01-12; completion 2026-04-15
- Results posted
- Not yet
This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.
From ClinicalTrials.gov, last updated 2026-08-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $27,079 in research payments for this study in 2025 (7 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Olatoyosi Odenike Hematology & Oncology · Chicago, IL
- Maria Baer, MD Hematology & Oncology · Baltimore, MD
- Meagan A. Jacoby, MD Medical Oncology · Saint Louis, MO
- Joseph G. Jurcic, MD Hematology · New York, NY
- Gail J. Roboz, MD Hematology & Oncology · New York, NY
- Jingzhou Hou Hematology & Oncology · Pittsburgh, PA
- Stephen A. Strickland JR., MD Hematology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Washington University in St Louis $11,890
- Cornell University Weill Medical College $8,344
- Vanderbilt University Medical Center, TN $2,897
- Columbia University Medical Center $2,246
- University of Chicago $1,000
- Maryland Board of Pharmacy $537
- University of Pittsburgh Cancer Institute $165
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.